Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.
Bias | Author's judgement | Support for judgement |
Randomization |
Low |
Quote: "Randomisation will be carried out by means of electronic case report forms (eCRFs). The ratio will be 1:1:1 for each group (balanced randomisation). The study design is open, but the investigator will not know the treatment assignment until the patient signs the informed consent form and randomisation is performed, thus minimising selection bias. Patients will be identified by a code that includes the centre code followed by the patient number (XX-YY)."
Comment: Allocation sequence random Allocation probably concealed. |
Deviations from intervention |
Low |
RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group "Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis." JAMA. 2021;326(6):499-518 due to unavailability of trial details. |
Missing outcome data |
Low |
RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group "Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis." JAMA. 2021;326(6):499-518 due to unavailability of trial details. |
Measurement of the outcome |
Low |
RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group "Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis." JAMA. 2021;326(6):499-518 due to unavailability of trial details. |
Selection of the reported results |
Low |
RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group "Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis." JAMA. 2021;326(6):499-518 due to unavailability of trial details. |
Overall risk of bias |
Low |